Back to Sectors

NUWE

Nuwellis, Inc.
2 filings tracked
healthcaremedical devicesMICRO (<$300M)

Signal Magnitude Chart

BEARISH | 70% | 5/15/2026 | earnings missBULLISH | 90% | 5/15/2026 | margin expansionNEUTRAL | 60% | 5/15/2026 | capital raiseBULLISH | 50% | 5/15/2026 | acquisitionBEARISH | 70% | 5/15/2026 | earnings missBULLISH | 90% | 5/15/2026 | margin expansionNEUTRAL | 60% | 5/15/2026 | capital raiseBULLISH | 50% | 5/15/2026 | acquisitionMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bearishMay 15

Net loss widened to $4.54 million due to increased operating expenses.

earnings miss
70%
bullishMay 15

Gross margin increased significantly to 70.1% via manufacturing optimization.

margin expansion
90%
neutralMay 15

Raised approximately $5 million through a PIPE and warrant inducement transaction.

capital raise
60%
bullishMay 15

Acquired Rendiatech to add automated kidney function monitoring technology.

acquisition
50%
bearishMay 15

Net loss widened to $4.54 million due to increased operating expenses.

earnings miss
70%
bullishMay 15

Gross margin increased significantly to 70.1% via manufacturing optimization.

margin expansion
90%
neutralMay 15

Raised approximately $5 million through a PIPE and warrant inducement transaction.

capital raise
60%
bullishMay 15

Acquired Rendiatech to add automated kidney function monitoring technology.

acquisition
50%

Filing History

10-QMay 15, 2026

The Q1 2026 filing presents a stark contrast between operational progress and financial instability. On one hand, the Aquadex system is seeing unprecedented demand and the company has successfully optimized its cost of goods sold. On the other hand, the company is fighting a battle against a depleting cash runway and a history of substantial accumulated deficits totaling $320.9 million. The integration of Rendiatech and the focus on the U.S. market are the primary catalysts for future growth, but these initiatives require capital that the company does not currently possess. Investors are left weighing the impressive 70% gross margins against a 'going concern' warning and the immediate need for additional financing. The ultimate success of the turnaround depends on whether the current sales momentum can be converted into cash flow before the company exhausts its remaining liquidity.